| 000 | 01767 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513135816.0 | ||
| 264 | 0 | _c19980319 | |
| 008 | 199803s 0 0 eng d | ||
| 022 | _a0160-6689 | ||
| 024 | 7 |
_a10.4088/jcp.v59n0205 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiller, C H | |
| 245 | 0 | 0 |
_aThe prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. _h[electronic resource] |
| 260 |
_bThe Journal of clinical psychiatry _cFeb 1998 |
||
| 300 |
_a69-75 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAkathisia, Drug-Induced _xdiagnosis |
| 650 | 0 | 4 | _aAmbulatory Care |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 |
_aClozapine _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 |
_aPsychotic Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aRisperidone _xadverse effects |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 700 | 1 | _aMohr, F | |
| 700 | 1 | _aUmbricht, D | |
| 700 | 1 | _aWoerner, M | |
| 700 | 1 | _aFleischhacker, W W | |
| 700 | 1 | _aLieberman, J A | |
| 773 | 0 |
_tThe Journal of clinical psychiatry _gvol. 59 _gno. 2 _gp. 69-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4088/jcp.v59n0205 _zAvailable from publisher's website |
| 999 |
_c9469943 _d9469943 |
||